Improved Process For Preparing Rivaroxaban Using Novel Ntermediates

SYMED LABS LIMITED
Granted App No 1701/CHE/2012 Patent 448487 Chemical

Patent information

IP India · live record
Application number
1701/CHE/2012
Filing date
02 May 2012
Status
Granted
Legal status
Inforce
Publication number
44/2015
Publication type
INA
Invention field
Chemical
Patent number
448487
Grant date
30 August 2023
Next renewal due
02 May 2027

Abstract

Provided herein is an industrially advantageous one-pot process for the preparation of rivaroxaban or a stereochemically isomeric form or a racemic mixture thereof, in high yield and purity, using novel intermediates.

Applicants

1
India
SYMED LABS LIMITED 8-3-166/6 & 7, II FLOOR, SREE ARCADE, ERRAGADDA, HYDERABAD - 500 018

Inventors

2
India
MOHAN RAO DODDA8-2-293/82/A/202, D.NO: 202, OPP.: JUBILEE INTERNATIONAL CLUB, ROAD NO: 14, JUBILEE HILLS, HYDERABAD - 500 033
India
VENKAT REDDY BUTHUKURIH.NO: 8-252-9/4, VENKANNA HILLS, CHINTAL, HYDERABAD - 500 054

Claims

18
1 A one-pot process for preparing rivaroxaban, 5-chloro-N-[[(5S)-2-oxo-3-[4-(3- oxomorpholin-4-yl)phenyl]oxazolidin-5-yl]methyl]thiophene-2-carboxamide, of formula I: or a stereochemically isomeric form or a racemic mixture thereof, comprising: a) reacting 5-chlorothiophene-2-carboxylic acid of formula IV: O or a salt thereof, with a sulfonylating agent of formula Va or Vb: wherein 'R' is an alkyl, cycloalkyl, haloalkyl, aralkyl, or substituted or unsubstituted aryl group; to produce a sulfonyl ester compound of formula III: wherein R is as defined above; b) reacting the sulfonyl ester compound of formula III with 4-[4-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl]morpholine-3-one of formula II: or a stereochemically isomeric form or a racemic mixture thereof, or an acid addition salt thereof, to produce the rivaroxaban of formula I or a stereochemically isomeric form or a racemic mixture thereof.
2 The process of claim 1, wherein the group 'R' in the compounds of formulae III, Va and Vb is selected from the group consisting of methyl, ethyl, propyl, isopropyl, isobutyl, chloromethyl, fluoromethyl, trifluoromethyl, phenyl, p-tolyl, benzyl, 4-nitrophenyl, 4-chlorophenyl, 3-nitrophenyl and 4-chlorobenzyl.
3 The process of claim 2, wherein the group 'R' in the compounds of formulae III, Va and Vb is methyl or p-tolyl.
4 The process of claim 1, wherein the one-pot process is carried out in the presence of a solvent or a mixture of solvents.
5 The process of claim 4, wherein the solvent is selected from the group consisting of a chlorinated hydrocarbon, an ester, a cyclic ether, an aliphatic ether, a hydrocarbon, a polar aprotic solvent, a nitrile, an alcohol, and mixtures thereof.
6 The process of claim 5, wherein the solvent is selected from the group consisting of dichloromethane, dichloroethane, chloroform, carbon tetrachloride, ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate, ethyl formate, tetrahydrofuran, 2-methyl tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, methyl tert-butyl ether, monoglyme, diglyme, n-pentane, n-hexane, n-heptane, cyclohexane, toluene, xylene, acetonitrile, propionitrile, 4-methylmorpholine, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, methanol, ethanol, isopropanol, n-butanol, and mixtures thereof.
7 The process of claim 6, wherein the solvent is dichloromethane.
8 The process of claim 1, wherein the one-pot process is carried out in the presence of a base, wherein the base is an organic or inorganic base; and wherein the salt of the compound of formula IV is derived from an organic or inorganic base.
9 The process of claim 8, wherein the base is an organic base; and wherein the salt of the compound of formula IV is derived from an organic base.
10 The process of claim 8, wherein the organic base is selected from the group consisting of trimethylamine, tributylamine, triethylamine, diisopropylethylamine, N-methylmorpholine, 4-(N,N-dimethylamino)pyridine and 1-alkylimidazole; and wherein the inorganic base is selected from the group consisting of sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, lithium carbonate, sodium tert- butoxide, sodium isopropoxide and potassium tert-butoxide.
11 The process of claim 10, wherein the organic base is 1-alkylimidazole or 4-(N,N-dimethylamino)pyridine.
12 The process of claim 11, wherein the organic base is 1-methylimidazole.
13 The process of claim 1, wherein the overall one-pot process is carried out at a temperature of about -15°C to about the boiling temperature of the solvent used.
14 The process of claim 13, wherein the overall one-pot process is carried out at a temperature of about -5°C to about 30°C.
15 A sulfonyl ester compound of formula III: wherein 'R' is an alkyl, cycloalkyl, haloalkyl, aralkyl, or substituted or unsubstituted aryl group.
16 The compound of claim 15, wherein the group 'R' is selected from the group consisting of methyl, ethyl, propyl, isopropyl, isobutyl, chloromethyl, fluoromethyl, trifluoromethyl, phenyl, p-tolyl, benzyl, 4-nitrophenyl, 4-chlorophenyl, 3-nitrophenyl and 4-chlorobenzyl.
17 The compound of claim 16, wherein the group 'R' is methyl or p-tolyl.
18 A process for preparing rivaroxaban of formula I: or a stereochemically isomeric form or a racemic mixture thereof, comprising reacting a sulfonyl ester compound of formula III: wherein 'R' is an alkyl, cycloalkyl, haloalkyl, aralkyl, or substituted or unsubstituted aryl group; with 4-[4-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl]morpholine-3-one of formula II: or a stereochemically isomeric form or a racemic mixture thereof, or an acid addition salt thereof, to produce the rivaroxaban of formula I or a stereochemically isomeric form or a racemic mixture thereof. 19. A process for preparing a sulfonyl ester compound of formula HI: wherein 'R' is an alkyl, cycloalkyl, haloalkyl, aralkyl, or substituted or unsubstituted aryl group; comprising reacting 5-chlorothiophene-2-carboxylic acid of formula IV: or a salt thereof, with a sulfonylating agent of formula Va or Vb: wherein 'R' is an alkyl, cycloalkyl, haloalkyl, aralkyl, or substituted or unsubstituted aryl group; to produce the sulfonyl ester compound of formula III. 20. Use of the sulfonyl ester compounds of formula III of any one of claims 15-17 in the process for manufacture of rivaroxaban, or a stereochemically isomeric form or a racemic mixture thereof.

Specification

Show full textCollapse

FIELD OF THE INVENTION

The present invention relates to a novel, commercially viable and industrially advantageous process for the preparation of rivaroxaban, in high yield and purity, using novel intermediates.

BACKGROUND OF THE INVENTION

PCT Publication No. WOO 1 /47919A1 (corresponding US equivalent patent No. US 7,585,860) discloses a variety of substituted oxazolidinone derivatives and their salts, processes for their preparation, pharmaceutical compositions comprising the derivatives, and methods of use thereof. These compounds are anticoagulants which inhibit the blood coagulation factor Xa with increased selectivity. Among them, Rivaroxaban, 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]oxazolidin-5-yl]methyl]thiophene-2-carboxamide, acts as inhibitor of clotting factor Xa and which is used as agent for the prophylaxis and/or treatment of thromboembolic disorders, in particular myocardial infarction, angina pectoris, reocclusions and restenoses after angioplasty or aortocoronary bypass, stroke, transient ischaemic attacks, peripheral arterial occlusive diseases, pulmonary embolisms or deep venous thromboses. Rivaroxaban is represented by the following structural formula I:

Rivaroxaban is sold by Bayer under the brand name Xarelto® and it is orally administered as tablets containing 10 mg of rivaroxaban.

Various processes for the preparation of rivaroxaban, its intermediates, and related compounds are disclosed in U.S. Patent Nos. 7,585,860; 7,351,823 and 7,816,355; PCT Publication Nos. WO2011/012321, WO2011/080341 and WO2011/098501; and J. Med. Chem. 2005, 48, 5900-5908.

According to U.S. Patent No. 7,585,860 (hereinafter referred to as the '860 patent), rivaroxaban is prepared by reacting 4-[4-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl]morpholine-3-one with 5-chlorothiophene-2-carbonyl chloride in the presences of excess amounts of pyridine. As per the process exemplified in example 44 of the '860 patent, rivaroxaban is prepared by drop-wise addition of 5-chlorothiophene-2-carbonyl chloride to a solution of 4-[4-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl]morpholine-3-one in pyridine at 0°C under argon, followed by removal of ice-cooling and stirring the reaction mixture at room temperature for 1 hour and then admixing with water. After addition of dichloromethane and phase separation, the aqueous phase was extracted with dichloromethane. The combined organic phases were dried, filtered, and evaporated in vacuo. The residue was purified by Flash chromatography (dichloromethane/methanol mixtures) to produce rivaroxaban.

According to U.S. Patent No. 7,351,823 (hereinafter referred to as the '823 patent), rivaroxaban is prepared by reacting 4-[4-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl]morpholine-3-one hydrochloride salt with 5-chlorothiophene-2-carbonyl chloride in the presence of an inorganic base, preferably sodium carbonate, in a solvent selected from the group consisting of ether, alcohol, ketone and water or in a mixture thereof. As per the process exemplified in the '823 patent, the preparation of rivaroxaban is carried out in three steps. According to the first step, 5-chlorothiophene-2-carbonyl chloride is prepared by reacting 5-chlorothiophene-2-carboxylic acid with thionyl chloride in toluene at a temperature of 75 to 80°C. According to the second step, 4-[4-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl]morpholine-3-one hydrochloride salt is reacted with 5-chlorothiophene-2-carbonyl chloride (30% strength solution in toluene) in the presence of sodium carbonate in a solvent mixture containing water and acetone to produce crude rivaroxaban. In third step, the solvent-containing crude product is purified by recrystallization from acetic acid.

The processes for the preparation of rivaroxaban described in the aforementioned prior art suffer from disadvantages such as the use of highly hazardous materials like thionyl chloride and pyridine, and use of tedious and cumbersome procedures like low temperatures, multiple process steps, column chromatographic purifications, multiple isolations/ re-crystallizations, recrystallization using corrosive acids like acetic acid, and thus resulting in a poor product yield and quality. Methods involving column chromatographic purifications are generally undesirable for large-scale operations, thereby making the process commercially unfeasible.

The main drawback of the processes for the preparation of rivaroxaban described in the aforementioned prior art is that the processes involve the use of highly corrosive and unstable acid chloride intermediate, 5-chlorothiophene-2-carbonyl chloride. Use of this unstable acid chloride intermediate is not advisable for scale up operations due to handling difficulties. Moreover, the process for the preparation of the acid chloride intermediate requires the use of highly hazardous and toxic reagents like thionyl chloride, phosgene and oxalyl chloride, which are highly corrosive and dangerous to environment. Handling of these reagents is very difficult on commercial scale operations.

The process for the preparation of rivaroxaban described in the '860 patent involves the use of excess amounts of pyridine, which is highly toxic chemical and dangerous to human health.

Based on the aforementioned drawbacks, the prior art processes have been found to be unsuitable for the preparation of rivaroxaban at lab scale and in commercial scale operations.

A need remains for an improved, commercially viable and environmentally friendly process of preparing rivaroxaban with high yield and purity, to resolve the problems associated with the processes described in the prior art, and that will be suitable for large-scale preparation. Desirable process properties include non-hazardous conditions, environmentally friendly and easy to handle reagents, reduced process steps, reduced reaction time periods, reduced cost, greater simplicity, increased purity, and increased yield of the product, thereby enabling the production of rivaroxaban in high purity and with high yield.

SUMMARY OF THE INVENTION The present inventors have surprisingly found that rivaroxaban of formula I can be prepared in a one-pot process, in high purity and with high yield, by reacting 5-chlorothiophene-2-carboxylic acid or a salt thereof with a sulfonylating agent to produce a sulfonyl ester intermediate, which is then condensed with 4-[4-[(5S)-5-(aminomethyI)-2-oxo-l,3-oxazolidin-3-yl]phenyl]morpholine-3-one or an acid addition salt thereof to produce rivaroxaban.

In one aspect, provided herein is an efficient, industrially advantageous and environmentally friendly process for the preparation of rivaroxaban, in high yield and with high chemical and enantiomeric purity, using novel intermediates. The process disclosed herein avoids the tedious and cumbersome procedures of the prior processes, thereby resolving the problems associated with the processes described in the prior art, which is more convenient to operate at lab scale and in commercial scale operations.

In another aspect, provided herein are novel sulfonyl ester compounds of formula III: wherein 'R' is an alkyl, cycloalkyl, haloalkyl, aralkyl, or substituted or unsubstituted aryl group.

In another aspect, the present invention also encompasses the use of novel sulfonyl ester intermediates of formula III disclosed herein for preparing rivaroxaban or a stereochemically isomeric form or a racemic mixture thereof.

The process for the preparation of rivaroxaban disclosed herein has the following advantages over the processes described in the prior art: i) the process is carried out in a single pot using novel intermediates, and it involves shorter reaction times and reduced quantities of reagents and solvents; ii) the process avoids the use of hazardous and corrosive chemicals like pyridine, thionyl chloride, and unstable acid chloride intermediate; iii) the process avoids the use of tedious and cumbersome procedures like column chromatographic purifications, multiple isolations/recrystallizations, and recrystallizations using corrosive acids such as acetic acid; iv) the process involves easy work-up methods and simple isolation processes, and there is a reduction in chemical waste; v) the purity of the product is increased without additional purifications; and vi) the overall yield of the product is increased.

DETAILED DESCRIPTION OF THE INVENTION

According to one aspect, there is provided a one-pot process for preparing rivaroxaban, 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorphoUn-4-yl)phenyl]oxazolidin-5-yl]methyl]thiophene-2-carboxamide, of formula I:

or a stereochemically isomeric form or a racemic mixture thereof, comprising: a) reacting 5-chlorothiophene-2-carboxylic acid of formula IV: or a salt thereof, with a sulfonylating agent of formula Va or Vb: wherein 'R' is an alkyl, cycloalkyl, haloalkyl, aralkyl, or substituted or unsubstituted aryl group; to produce a sulfonyl ester compound of formula III: wherein R is as defined above; and b) reacting the sulfonyl ester compound of formula III with 4-[4-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl]morpholine-3-one of formula II: or a stereochemically isomeric form or a racemic mixture thereof, or an acid addition salt thereof, to produce the rivaroxaban of formula I or a stereochemically isomeric form or a racemic mixture thereof.

The structural formula of rivaroxaban contains one chiral centre and thus exists as two optical isomers, i.e. enantiomers (R & S-isomers). The process disclosed herein encompasses the preparation of both enantiomers and mixtures thereof in all proportions.

The term "alkyl", as used herein, denotes an aliphatic hydrocarbon group which may be straight or branched having 1 to 12 carbon atoms in the chain. Preferred alkyl groups have 1 to 6 carbon atoms in the chain. The alkyl may be substituted with one or more "cycloalkyl groups". Exemplary alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl, t-butyl, and n-pentyl.

The term "cycloalkyl", as used herein, denotes a non-aromatic mono- or multicyclic ring system of 3 to 10 carbon atoms, preferably of about 5 to about 10 carbon atoms. Exemplary monocyclic cycloalkyl groups include cyclopentyl, cyclohexyl, cycloheptyl and the like.

The term "aralkyl", as used herein, denotes an aryl-alkyl group wherein the aryl and alkyl are as herein described. Preferred aralkyls contain a lower alkyl moiety. Exemplary aralkyl groups include benzyl, 2-phenethyl and naphthalenemethyl.

The term "aryl", as used herein, denotes an aromatic monocyclic or multicyclic ring system of 6 to 10 carbon atoms. The aryl is optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein. Exemplary aryl groups include phenyl, tolyl or naphthyl.

Specifically, the group 'R' in the compounds of formulae III, Va and Vb is selected from the group consisting of methyl, ethyl, propyl, isopropyl, isobutyl, chloromethyl, fluoromethyl, trifluoromethyl, phenyl, p-tolyl, benzyl, 4-nitrophenyl, 4-chlorophenyl, 3-nitrophenyl, 4-chlorobenzyl, and the like; and most specifically, R is methyl or p-tolyl.

The sulfonyl ester compounds of formula III are novel and form another aspect of the present invention.

The use of the sulfonyl ester compounds of formula III in the process for manufacture of rivaroxaban, or a stereochemically isomeric form or a racemic mixture thereof, is novel and forms further aspect of the present invention.

In one embodiment, the one-pot process disclosed herein is carried out in the presence of a solvent or a mixture of solvents.

Exemplary solvents used in the one-pot process include, but are not limited to, a chlorinated hydrocarbon, an ester, a cyclic ether, an aliphatic ether, a hydrocarbon, a polar aprotic solvent, a nitrile, an alcohol, and mixtures thereof; and most specifically a chlorinated hydrocarbon solvent.

Specifically, the solvent is selected from the group consisting of dichloromethane, dichloroethane, chloroform, carbon tetrachloride, ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate, ethyl formate, tetrahydrofuran, 2-methyl tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, methyl tert-butyl ether, monoglyme, diglyme, n-pentane, n-hexane, n-heptane, cyclohexane, toluene, xylene, acetonitrile, propionitrile, 4-methylmorpholine, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, methanol, ethanol, isopropanol, n-butanol, and mixtures thereof. A most specific solvent is dichloromethane.

In one embodiment, the one-pot process disclosed herein is carried out in the presence of a base. Specifically, the base is an organic or inorganic base, and most specifically an organic base.

Exemplary organic bases include, but are not limited to, trimethylamine, tributylamine, triethylamine, diisopropylethylamine, N-methylmorpholine, 4-(N,N-dimethylamino)pyridine and 1-alkylimidazole. Specific organic bases are 1-alkylimidazole and 4-(N,N-dimethylamino)pyridine, and more specifically 1-methylimidazole.

Exemplary inorganic bases include, but are not limited to, hydroxides, alkoxides, bicarbonates and carbonates of alkali or alkaline earth metals. Specific inorganic bases are sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, lithium carbonate, sodium tert- butoxide, sodium isopropoxide and potassium tert-butoxide.

In one embodiment, the base is used, in the process disclosed herein, in a ratio of about 1 to 4 equivalents, specifically about 1.5 to 3.5 equivalents, with respect to the compound of formula IV in order to ensure a proper course of the reaction.

In another embodiment, the 5-chlorothiophene-2-carboxylic acid of formula IV is used in the form a salt. The salt of the compound of formula IV is derived from an organic or inorganic base selected from the group as described above. Specifically, the salt of the compound of formula IV is derived from an organic base.

Exemplary acid addition salts of the amine compound of formula II include, but are not limited to, hydrochloride, hydrobromide, sulfate, nitrate, phosphate, acetate, propionate, oxalate, succinate, maleate, fumarate, benzenesulfonate, toluenesulfonate, citrate, and tartrate.

The overall one-pot process is carried out at a temperature of about -15°C to about the boiling temperature of the solvent used, specifically at a temperature of about -10°C to about 50°C, and more specifically at a temperature of about -5°C to about 30°C. The reaction time may vary from about 30 minutes to about 15 hours, specifically from about 1 hour to about 10 hours, and more specifically from about 2 hours to about 5 hours.

The reaction mass containing the rivaroxaban of formula I obtained may be subjected to usual work up such as a washing, an extraction, an evaporation, a pH adjustment etc., followed by isolation and/or recrystallization from a suitable solvent by conventional methods such as cooling, seeding, partial removal of the solvent from the solution, by adding an anti-solvent to the solution, evaporation, vacuum distillation, or a combination thereof.

The solvent used for isolating/recrystallizing the pure rivaroxaban of formula I is selected from the group consisting of water, acetone, methanol, ethanol, n-propanol, isopropanol, ethyl acetate, dichloromethane, toluene, N,N-dimethyformamide, dimethylsulfoxide, acetonitrile, acetic acid, and mixtures thereof. More specifically, the solvent is a mixture of water and dichloromethane.

In one embodiment, the isolation is carried out by adding water to the reaction mixture at a temperature of about 10°C to about 35°C, and more specifically at a temperature of about 20°C to about 30°C. After completion of addition process, the resulting mass is stirred at a temperature of about 10°C to about 35°C for at least 10 minutes, and most specifically at a temperature of about 20°C to about 30°C for about 15 minutes to about 2 hours.

The solid obtained is collected by filtration, filtration under vacuum, decantation, centrifugation, filtration employing a filtration media of a silica gel or celite, or a combination thereof.

The sulfonyl ester intermediate of formula III employed for the coupling reaction disclosed herein allows the product to be easily isolated and purified, thereby producing a product with 85-95% overall yield.

The highly pure rivaroxaban, or a stereochemically isomeric form or a racemic mixture thereof, obtained by the above process may be further dried in, for example, a Vacuum Tray Dryer, a Rotocon Vacuum Dryer, a Vacuum Paddle Dryer or a pilot plant Rota vapor, to further lower residual solvents. Drying can be carried out under reduced pressure until the residual solvent content reduces to the desired amount such as an amount that is within the limits given by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use ("ICH") guidelines.

In one embodiment, the drying is carried out at atmospheric pressure or reduced pressures, such as below about 200 mm Hg, or below about 50 mm Hg, at temperatures such as about 35°C to about 90°C, and specifically at about 75°C to about 85°C. The drying can be carried out for any desired time period that achieves the desired result, such as times about 1 to 20 hours. Drying may also be carried out for shorter or longer periods of time depending on the product specifications. Temperatures and pressures will be chosen based on the volatility of the solvent being used and the foregoing should be considered as only a general guidance. Drying can be suitably carried out in a tray dryer, vacuum oven, air oven, or using a fluidized bed drier, spin flash dryer, flash dryer, and the like.

In another embodiment, the highly pure rivaroxaban obtained by the process disclosed herein has a total purity, includes both chemical and enantiomeric purity, of greater than about 99%, specifically greater than about 99.5%, more specifically greater than about 99.9%, and most specifically greater than about 99.95% as measured by HPLC. The HPLC purities were measured as per the method and conditions reported in column-2 of page No. 5905 of J. Med. Chem. 2005,48, 5900-5908.

According to another aspect, there is provided a process for preparing rivaroxaban of formula I:

or a stereochemically isomeric form or a racemic mixture thereof, comprising reacting a sulfonyl ester compound of formula III:

wherein R is as defined above;

with 4-[4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl]morpholine-3-one of formula II:

or a stereochemically isomeric form or a racemic mixture thereof, or an acid addition salt thereof, to produce the rivaroxaban of formula I or a stereochemically isomeric form or a racemic mixture thereof.

According to another aspect, there is provided a process for preparing a sulfonyl ester compound of formula III:

wherein R is as defined above; comprising reacting 5-chlorothiophene-2-carboxylic acid of formula IV:

or a salt thereof, with a sulfonylating agent of formula Va or Vb:

wherein 'R' is an alkyl, cycloalkyl, haloalkyl, aralkyl, or substituted or unsubstituted aryl group; to produce the sulfonyl ester compound of formula III.

According to another aspect, there is provided a novel sulfonyl ester compound of formula III:

wherein 'R' is an alkyl, cycloalkyl, haloalkyl, aralkyl, or substituted or unsubstituted aryl group.

Specifically, the group 'R' in the compounds of formula III is selected from the group consisting of methyl, ethyl, propyl, isopropyl, isobutyl, chloromethyl, fluoromethyl, trifluoromethyl, phenyl, p-tolyl, benzyl, 4-nitrophenyl, 4-chlorophenyl, 3-nitrophenyl, 4-chlorobenzyl, and the like; and most specifically, R is methyl or p-tolyl.

The following examples are given for the purpose of illustrating the present invention and should not be considered as limitation on the scope or spirit of the invention.

EXAMPLES Example 1 Preparation of Rivaroxaban

1-Methylimidazole (24.6 g, 0.3 mol) was added to a stirred suspension of 5-chlorothiophene-2-carboxylic acid (16.25 g, 0.1 mol) in dichloromethane (162 ml) at 0-5°C and the resulting solution was stirred for 10 minutes. A solution of methanesulfonyl chloride (12 g, 0.105 mol) in dichloromethane (40 ml) was added to the above solution at -5°C. The resulting solution was stirred for 1 hour at -5°C to produce a reaction mass containing the sulfonyl ester intermediate, followed by portion wise addition of 4-[4-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl] morpholine-3-one (29.1 g, 0.1 mol, chiral purity: 99.9%). The reaction mixture was stirred for 2 hours at 25-30°C, followed by the addition of water (162 ml) and then stirring for 15 minutes. The separated solid was filtered, washed with dichloromethane (50 ml) and water (100 ml), and the resulting wet material was dried at 80-85°C for 3 to 5 hours to produce 39.2 g of pure rivaroxaban as a white crystalline solid (Theoretical Yield: 90%; Purity by HPLC: 99.9%; and Chiral Purity by HPLC: 99.9%).

Example 2 Preparation of Rivaroxaban

4-(N,N-dimethylamino)pyridine (36.6 g, 0.3 mol) was added to a stirred suspension of 5-chlorothiophene-2-carboxylic acid (16.25 g, 0.1 mol) in dichloromethane (162 ml) at 0-5°C and the resulting solution was stirred for 10 minutes. A mixture of p-toluenesulfonyl chloride (19.05 g, 0.1 mol) and dichloromethane (50 ml) was added to the above solution at -5°C. The resulting solution was stirred for 1 hour at -5°C to produce a reaction mass containing the sulfonyl ester intermediate, followed by portion wise addition of 4-[4-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl] morpholine-3-one (29.1 g, 0.1 mol, chiral purity: 99.9%). The reaction mixture was stirred for 2 hours at 25-30°C, followed by the addition of water (162 ml) and then stirring for 15 minutes. The separated solid was filtered, washed with dichloromethane (50 ml) and water (100 ml), and the resulting wet material was dried at 80-85°C for 3 to 5 hours to produce 37.3 g of pure rivaroxaban as a white crystalline solid (Theoretical Yield: 85.6%; Purity by HPLC: 99.9%; and Chiral Purity by HPLC: 99.9%).

Example 3 Preparation of Rivaroxaban 1-Methylimidazole (20.5 g, 0.25 mol) was added to a stirred suspension of 5-chlorothiophene-2-carboxylic acid (16.25 g, 0.1 mol) in dichloromethane (162 ml) at 0-5°C and the resulting solution was stirred for 10 minutes. A solution of methanesulfonic anhydride (17.4 g, 0.1 mol) in dichloromethane (40 ml) was added to the above solution at -5°C. The resulting solution was stirred for 1 hour at -5°C to produce a reaction mass containing the sulfonyl ester intermediate, followed by portion wise addition of 4-[4-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl] morpholine-3-one (29.1 g, 0.1 mol, chiral purity by HPLC: 99.85%). The reaction mixture was stirred for 2 hours at 25-30°C, followed by the addition of water (162 ml) and then stirring for 15 minutes. The separated solid was filtered, washed with dichloromethane (50 ml) and water (100 ml), and the resulting wet material was dried at 80-85°C for 3 to 5 hours to produce 38.5 g of pure rivaroxaban as a white crystalline solid (Theoretical Yield: 88.4%; Purity by HPLC: 99.8%; and Chiral Purity by HPLC: 99.85%).

Example 4 Preparation of 5-ChIoro-N-[[2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]oxazoIidin-5-yl]methyl]thiophene-2-carboxamide (Racemic rivaroxaban) 1-Methylimidazole (24.6 g, 0.3 mol) was added to a stirred suspension of 5-chlorothiophene-2-carboxylic acid (16.25 g, 0.1 mol) in dichloromethane (162 ml) at 0-5°C and the resulting solution was stirred for 10 minutes. A solution of methanesulfonyl chloride (12 g, 0.105 mol) in dichloromethane (40 ml) was added to the above solution at -5°C. The resulting solution was stirred for 1 hour at -5°C to produce a reaction mass containing the sulfonyl ester intermediate, followed by portion wise addition of racemic 4-[4-[5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl] morpholine-3-one (29.1 g, 0.1 mol). The reaction mixture was stirred for 2 hours at 25-30°C, followed by the addition of water (162 ml) and then stirring for 15 minutes. The separated solid was filtered, washed with dichloromethane (50 ml) and water (100 ml), and the resulting wet material was dried at 80-85°C for 3 to 4 hours to produce 39.1 g of pure racemic 5-chloro.-N-[[2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]oxazolidin-5-yl]methyl]thiophene-2-carboxamide as a white crystalline solid (Theoretical Yield: 90%; Purity by HPLC: 99.9%).

All ranges disclosed herein are inclusive and combinable. While the invention has been described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention will include all embodiments falling within the scope of the appended claims.

We claim:

1. A one-pot process for preparing rivaroxaban, 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]oxazolidin-5-yl]methyl]thiophene-2-carboxamide, of formula I:

or a stereochemically isomeric form or a racemic mixture thereof, comprising: a) reacting 5-chlorothiophene-2-carboxylic acid of formula IV:

O or a salt thereof, with a sulfonylating agent of formula Va or Vb:

wherein 'R' is an alkyl, cycloalkyl, haloalkyl, aralkyl, or substituted or unsubstituted aryl group; to produce a sulfonyl ester compound of formula III:

wherein R is as defined above; b) reacting the sulfonyl ester compound of formula III with 4-[4-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl]morpholine-3-one of formula II:

or a stereochemically isomeric form or a racemic mixture thereof, or an acid addition salt thereof, to produce the rivaroxaban of formula I or a stereochemically isomeric form or a racemic mixture thereof.

2. The process of claim 1, wherein the group 'R' in the compounds of formulae III, Va and Vb is selected from the group consisting of methyl, ethyl, propyl, isopropyl, isobutyl, chloromethyl, fluoromethyl, trifluoromethyl, phenyl, p-tolyl, benzyl, 4-nitrophenyl, 4-chlorophenyl, 3-nitrophenyl and 4-chlorobenzyl.

3. The process of claim 2, wherein the group 'R' in the compounds of formulae III, Va and Vb is methyl or p-tolyl.

4. The process of claim 1, wherein the one-pot process is carried out in the presence of a solvent or a mixture of solvents.

5. The process of claim 4, wherein the solvent is selected from the group consisting of a chlorinated hydrocarbon, an ester, a cyclic ether, an aliphatic ether, a hydrocarbon, a polar aprotic solvent, a nitrile, an alcohol, and mixtures thereof.

6. The process of claim 5, wherein the solvent is selected from the group consisting of dichloromethane, dichloroethane, chloroform, carbon tetrachloride, ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate, ethyl formate, tetrahydrofuran, 2-methyl tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, methyl tert-butyl ether, monoglyme, diglyme, n-pentane, n-hexane, n-heptane, cyclohexane, toluene, xylene, acetonitrile, propionitrile, 4-methylmorpholine, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, methanol, ethanol, isopropanol, n-butanol, and mixtures thereof.

7. The process of claim 6, wherein the solvent is dichloromethane.

8. The process of claim 1, wherein the one-pot process is carried out in the presence of a base, wherein the base is an organic or inorganic base; and wherein the salt of the compound of formula IV is derived from an organic or inorganic base.

9. The process of claim 8, wherein the base is an organic base; and wherein the salt of the compound of formula IV is derived from an organic base.

10. The process of claim 8, wherein the organic base is selected from the group consisting of trimethylamine, tributylamine, triethylamine, diisopropylethylamine, N-methylmorpholine, 4-(N,N-dimethylamino)pyridine and 1-alkylimidazole; and wherein the inorganic base is selected from the group consisting of sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, lithium carbonate, sodium tert- butoxide, sodium isopropoxide and potassium tert-butoxide.

11. The process of claim 10, wherein the organic base is 1-alkylimidazole or 4-(N,N-dimethylamino)pyridine.

12. The process of claim 11, wherein the organic base is 1-methylimidazole.

13. The process of claim 1, wherein the overall one-pot process is carried out at a temperature of about -15°C to about the boiling temperature of the solvent used.

14. The process of claim 13, wherein the overall one-pot process is carried out at a temperature of about -5°C to about 30°C.

15. A sulfonyl ester compound of formula III:

wherein 'R' is an alkyl, cycloalkyl, haloalkyl, aralkyl, or substituted or unsubstituted aryl group.

16. The compound of claim 15, wherein the group 'R' is selected from the group consisting of methyl, ethyl, propyl, isopropyl, isobutyl, chloromethyl, fluoromethyl, trifluoromethyl, phenyl, p-tolyl, benzyl, 4-nitrophenyl, 4-chlorophenyl, 3-nitrophenyl and 4-chlorobenzyl.

17. The compound of claim 16, wherein the group 'R' is methyl or p-tolyl.

18. A process for preparing rivaroxaban of formula I:

or a stereochemically isomeric form or a racemic mixture thereof, comprising reacting a sulfonyl ester compound of formula III:

wherein 'R' is an alkyl, cycloalkyl, haloalkyl, aralkyl, or substituted or unsubstituted aryl group;

with 4-[4-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl]morpholine-3-one of formula II:

or a stereochemically isomeric form or a racemic mixture thereof, or an acid addition salt thereof, to produce the rivaroxaban of formula I or a stereochemically isomeric form or a racemic mixture thereof. 19. A process for preparing a sulfonyl ester compound of formula HI:

wherein 'R' is an alkyl, cycloalkyl, haloalkyl, aralkyl, or substituted or unsubstituted aryl group; comprising reacting 5-chlorothiophene-2-carboxylic acid of formula IV:

or a salt thereof, with a sulfonylating agent of formula Va or Vb:

wherein 'R' is an alkyl, cycloalkyl, haloalkyl, aralkyl, or substituted or unsubstituted aryl group; to produce the sulfonyl ester compound of formula III. 20. Use of the sulfonyl ester compounds of formula III of any one of claims 15-17 in the process for manufacture of rivaroxaban, or a stereochemically isomeric form or a racemic mixture thereof.

Documents

Sign in to open
Orders
Section
Application documents
1 1701-CHE-2012 FORM-5 02-05-2012.pdf 02 May 2012
2 1701-CHE-2012 FORM-3 02-05-2012.pdf 02 May 2012
3 1701-CHE-2012 FORM-2 02-05-2012.pdf 02 May 2012
4 1701-CHE-2012 FORM-1 02-05-2012.pdf 02 May 2012
5 1701-CHE-2012 DESCRIPTION (COMPLETE) 02-05-2012.pdf 02 May 2012
6 1701-CHE-2012 CORRESPONDENCE OTHERS 02-05-2012.pdf 02 May 2012
7 1701-CHE-2012 CLAIMS 02-05-2012.pdf 02 May 2012
8 1701-CHE-2012 ABSTRACT 02-05-2012.pdf 02 May 2012
9 1701-CHE-2012 FORM-3 10-01-2013.pdf 10 Jan 2013
10 1701-CHE-2012 CORRESPONDENCE OTHERS 10-01-2013.pdf 10 Jan 2013
11 1701-CHE-2012 FORM-3 14-06-2013.pdf 14 Jun 2013
12 1701-CHE-2012 CORRESPONDENCE OTHERS 14-06-2013.pdf 14 Jun 2013
13 1701-CHE-2012 FORM-3 10-12-2013.pdf 10 Dec 2013
14 1701-CHE-2012 CORRESPONDENCE OTHERS 10-12-2013.pdf 10 Dec 2013
15 1701-CHE-2012 FORM-18 20-12-2013.pdf 20 Dec 2013
16 1701-CHE-2012 FORM-18 20-12-2013..pdf 20 Dec 2013
17 1701-CHE-2012 CORRESPONDENCE OTHERS 20-12-2013.pdf 20 Dec 2013
18 1701-CHE-2012 FORM-3 23-06-2014.pdf 23 Jun 2014
19 1701-CHE-2012 CORRESPONDENCE OTHERS 23-06-2014.pdf 23 Jun 2014
20 1701-CHE-2012 FORM-3 02-02-2015..pdf 02 Feb 2015
21 1701-CHE-2012 CORRESPONDANCE OTHERS 02-02-2015..pdf 02 Feb 2015
22 1701-CHE-2012 FORM-3 06-04-2015.pdf 06 Apr 2015
23 1701-CHE-2012 CORRESPONDENCE OTHERS 06-04-2015.pdf 06 Apr 2015
24 1701-CHE-2012FORM-3 10-08-2015.pdf 10 Aug 2015
25 1701-CHE-2012 CORRESPONDENCE OTHERS 10-08-2015.pdf 10 Aug 2015
26 1701-CHE-2012-OTHERS-250915.pdf 30 Nov 2015
27 1701-CHE-2012-Form 13-250915.pdf 30 Nov 2015
28 1701-CHE-2012-Correspondence-250915.pdf 30 Nov 2015
29 1701-CHE-2012-Form 3-181215.pdf 10 Jun 2016
30 1701-CHE-2012-Correspondence-F3-Copy of office action181215.pdf 10 Jun 2016
31 1701-CHE-2012-Copy of office action-181215.pdf 10 Jun 2016
32 1701-CHE-2012-OFFICE ACTION-250416.pdf 13 Jul 2016
33 1701-CHE-2012-Form 3-250416.pdf 13 Jul 2016
34 1701-CHE-2012-Correspondence-F1-OFFICE ACTION-250416.pdf 13 Jul 2016
35 1701-CHE-2012-OFFICE ACTION-250716.pdf 02 Aug 2016
36 1701-CHE-2012-Form 3-250716.pdf 02 Aug 2016
37 1701-CHE-2012-Correspondence--OFFICE ACTION-F3-250716.pdf 02 Aug 2016
38 Form 3_After Filing_22-09-2016.pdf 22 Sep 2016
39 Correspondence by Applicant_Form-3_22-09-2016.pdf 22 Sep 2016
40 Copy of Granted Patent_As Filed_22-09-2016.pdf 22 Sep 2016
41 Form3_After Filing_02-01-2017.pdf 02 Jan 2017
42 Correspondence by Agent_Form3_02-01-2017.pdf 02 Jan 2017
43 Australian_First office Action_02-01-2017.pdf 02 Jan 2017
44 Form3_After Filling_27-03-2017.pdf 27 Mar 2017
45 European_Office Action_27-03-2017.pdf 27 Mar 2017
46 Correspondence by Applicant_Form3_27-03-2017.pdf 27 Mar 2017
47 Form 3_After Filing_04-08-2017.pdf 04 Aug 2017
48 Correspondence by Applicant_Form-3_04-08-2017.pdf 04 Aug 2017
49 Copy of Granted Patent_As Filed_04-08-2017.pdf 04 Aug 2017
50 1701-CHE-2012-FER.pdf 21 Nov 2017
51 Search Report_After Filing_15-01-2018.pdf 15 Jan 2018
52 Form 3_After Filing_15-01-2018.pdf 15 Jan 2018
53 Correspondence by Applicant_Form 3-Search Report_15-01-2018.pdf 15 Jan 2018
54 1701-CHE-2012-Changing Name-Nationality-Address For Service [14-03-2018(online)].pdf 14 Mar 2018
55 1701-CHE-2012-FER_SER_REPLY [15-03-2018(online)].pdf 15 Mar 2018
56 1701-CHE-2012-COMPLETE SPECIFICATION [15-03-2018(online)].pdf 15 Mar 2018
57 1701-CHE-2012-FORM-26 [22-03-2018(online)].pdf 22 Mar 2018
58 1701-CHE-2012-FER_SER_REPLY [22-03-2018(online)].pdf 22 Mar 2018
59 1701-CHE-2012-FORM-26 [04-04-2018(online)].pdf 04 Apr 2018
60 Correspondence by Agent_Power of Attorney_06-04-2018.pdf 06 Apr 2018
61 1701-CHE-2012-PRE GRANT OPPOSITION FORM [20-06-2018(online)].pdf 20 Jun 2018
62 1701-CHE-2012-PRE GRANT OPPOSITION DOCUMENT [20-06-2018(online)].pdf 20 Jun 2018
63 1701-CHE-2012-FORM-26 [20-06-2018(online)].pdf 20 Jun 2018
64 1701-CHE-2012-Statement and Evidence (MANDATORY) [19-09-2018(online)].pdf 19 Sep 2018
65 1701-CHE-2012-Retyped Pages under Rule 14(1) (MANDATORY) [19-09-2018(online)].pdf 19 Sep 2018
66 1701-CHE-2012-Annexure (Optional) [19-09-2018(online)].pdf 19 Sep 2018
67 1701-CHE-2012-2. Marked Copy under Rule 14(2) (MANDATORY) [19-09-2018(online)].pdf 19 Sep 2018
68 Correspondence by Applicant_Form 3_26-09-2018.pdf 26 Sep 2018
69 Correspondence by Applicant_Affidavit,Verification_26-09-2018.pdf 26 Sep 2018
70 1701-CHE-2012-PETITION UNDER RULE 138 [06-03-2020(online)].pdf 06 Mar 2020
71 1701-CHE-2012-PETITION UNDER RULE 137 [06-03-2020(online)].pdf 06 Mar 2020
72 1701-CHE-2012-Form 3_After Filing _02-11-2020.pdf 02 Nov 2020
73 1701-CHE-2012-Correspondence_office Action_02-11-2020.pdf 02 Nov 2020
74 1701-CHE-2012-Brazilian office action_After Filing_02-11-2020.pdf 02 Nov 2020
75 1701-CHE-2012-Form-3_After Filling_10-02-2021.pdf 10 Feb 2021
76 1701-CHE-2012-Correspondence-10-02-2021.pdf 10 Feb 2021
77 1701-CHE-2012-Copy of Brazilian Granted Patent And Copy of Granted Text_10-02-2021.pdf 10 Feb 2021
78 1701-CHE-2012-Form-3_After Filling_27-09-2021.pdf 27 Sep 2021
79 1701-CHE-2012-Decision to Grant, Granted Patent And Certificate of a European patent_27-09-2021.pdf 27 Sep 2021
80 1701-CHE-2012-Correspondence-27-09-2021.pdf 27 Sep 2021
81 1701-CHE-2012-PreGrant-HearingNotice-(HearingDate-08-07-2022).pdf 01 Jun 2022
82 1701-CHE-2012-RELEVANT DOCUMENTS [15-06-2022(online)].pdf 15 Jun 2022
83 1701-CHE-2012-POA [15-06-2022(online)].pdf 15 Jun 2022
84 1701-CHE-2012-FORM 13 [15-06-2022(online)].pdf 15 Jun 2022
85 1701-CHE-2012-AMENDED DOCUMENTS [15-06-2022(online)].pdf 15 Jun 2022
86 1701-CHE-2012-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [04-07-2022(online)].pdf 04 Jul 2022
87 1701-CHE-2012-PreGrant-ExtendedHearingNotice-(HearingDate-23-08-2022).pdf 07 Jul 2022
88 1701-CHE-2012-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [19-08-2022(online)].pdf 19 Aug 2022
89 1701-CHE-2012-PreGrant-ExtendedHearingNotice-(HearingDate-22-09-2022).pdf 22 Aug 2022
90 1701-CHE-2012-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [20-09-2022(online)].pdf 20 Sep 2022
91 1701-CHE-2012-PreGrant-ExtendedHearingNotice-(HearingDate-26-10-2022).pdf 20 Sep 2022
92 1701-CHE-2012-Correspondence to notify the Controller [22-10-2022(online)].pdf 22 Oct 2022
93 1701-CHE-2012-FORM-26 [25-10-2022(online)].pdf 25 Oct 2022
94 1701-CHE-2012-Correspondence to notify the Controller [25-10-2022(online)].pdf 25 Oct 2022
95 1701-CHE-2012-Written submissions and relevant documents [09-11-2022(online)].pdf 09 Nov 2022
96 1701-CHE-2012-Written submissions and relevant documents [10-11-2022(online)].pdf 10 Nov 2022
97 1701-CHE-2012-Written submissions and relevant documents [10-11-2022(online)]-1.pdf 10 Nov 2022
98 1701-CHE-2012-PETITION UNDER RULE 137 [10-11-2022(online)].pdf 10 Nov 2022
99 1701-CHE-2012-PatentCertificate30-08-2023.pdf 30 Aug 2023
100 1701-CHE-2012-IntimationOfGrant30-08-2023.pdf 30 Aug 2023
101 1701-CHE-2012-FORM 4 [06-05-2024(online)].pdf 06 May 2024
102 1701-CHE-2012-Response to office action [26-09-2025(online)].pdf 26 Sep 2025
Search strategy
11701CHE2012_14-11-2017.pdf

ERegister / renewals

Inforce
3rd Renewed 24 Nov 2023 Period 02 May 2014 – 02 May 2015 · CBR 54440 · Certificate 107287 ₹4,000
4th Renewed 24 Nov 2023 Period 02 May 2015 – 02 May 2016 · CBR 54440 · Certificate 107288 ₹4,000
5th Renewed 24 Nov 2023 Period 02 May 2016 – 02 May 2017 · CBR 54440 · Certificate 107289 ₹4,000
6th Renewed 24 Nov 2023 Period 02 May 2017 – 02 May 2018 · CBR 54440 · Certificate 107290 ₹4,000
7th Renewed 24 Nov 2023 Period 02 May 2018 – 02 May 2019 · CBR 54440 · Certificate 107291 ₹12,000
8th Renewed 24 Nov 2023 Period 02 May 2019 – 02 May 2020 · CBR 54440 · Certificate 107292 ₹12,000
9th Renewed 24 Nov 2023 Period 02 May 2020 – 02 May 2021 · CBR 54440 · Certificate 107293 ₹12,000
10th Renewed 24 Nov 2023 Period 02 May 2021 – 02 May 2022 · CBR 54440 · Certificate 107294 ₹12,000
11th Renewed 24 Nov 2023 Period 02 May 2022 – 02 May 2023 · CBR 54440 · Certificate 107295 ₹24,000
12th Renewed 24 Nov 2023 Period 02 May 2023 – 02 May 2024 · CBR 54440 · Certificate 107296 ₹24,000
13th Renewed 06 May 2024 Period 02 May 2024 – 02 May 2025 · CBR 30221 · Certificate 89605 ₹24,000
14th Renewed 02 May 2025 Period 02 May 2025 – 02 May 2026 · CBR 26506 · Certificate 33810 ₹24,000
15th Renewed 30 Apr 2026 Period 02 May 2026 – 02 May 2027 · CBR 36658 · Certificate 35279 ₹24,000